Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive management versus standard care in early psoriatic arthritis
ISRCTN30147736Phase 4Completed
- Sponsor
- University of Leeds
- Start
- May 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 4, randomised, open-label trial of methotrexate in psoriatic arthritis (PsA) (2 arms), sponsored by University of Leeds. Primary endpoint: ACR20 response at 12 months. Started May 2008; status: completed.
02
Drugs
methotrexate
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on ISRCTN30147736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN30147736.